|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Highly sensitive high-performance liquid chromatographic assay for 1-D-arabinofuranosylcytosine-5'-stearyl phosphate (cytarabine-ocfosfate)显示文摘 | Ramsauer B Braess J Unterhalt M | 1995 | J Chromatogr B:Biomed Appl1995，665，1： | 1 |
| 2 | The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated AML with a normal karyotype显示文摘 | SCHNEIDER F HOSTER E UNTERHALT M | 2012 | Blood2012，119，： | 1 |
| 3 | Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphoma:A phase Ⅱ study of the German low-grade Non-Hodgkin's lymphoma study Group 显示文摘 | Hiddeman W Unterhalt M Pott C | 1993 | Semin Oncol1993，20，： | 1 |
| 4 | De novo AML with dysplastichematopoiesis:cytogenetic and prognostic significance显示文摘 | Gahn B Haase D Unterhalt M | 1996 | Leukemi-a1996，10，6： | 1 |
| 5 | Maintenance therapy with rituximalo leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab,fludarabine, eyclophosphamide, and mitoxantmne ( R - FCM) in patients with recurring and refractory follicular and mantle cell lymphomas : results of a prospective randomized study of the German Low Grade Lymphoma Study Group ( GLSG ) 显示文摘 | Forstpointner R Unterhalt M Dreyling M | 2006 | Blood2006，108，13： | 1 |
| 6 | Rituximab plus chemotherapy in follicular and mantle cell lymphomas显示文摘 | Hiddemann W Drelying M Unterhalt M | 2003 | Semin Oncol2003，30，12： | 1 |
| 7 | The FLT31TD mRNA level has a high prognostic impact in NPM1 mutated,but not in NPM1unmutated,AML with a normal karyotype显示文摘 | Schneider F Hoster E Unterhalt M | 2012 | Blood2012，119，： | 1 |
| 8 | IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-Ⅱ study of the German Low- Grade Lymphoma Study Group 显示文摘 | Feuring-Buske M Kneba M Unterhalt M | 2000 | Ann Hematol2000，79，9： | 1 |
| 9 | Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (RFCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)显示文摘 | Forstpointner R Unterhalt M Dreyling M | 2006 | Blood2006，108，13： | 1 |
| 10 | Fludarabine single-agent phase Ⅱ study of the German low-grade non-Hodgkin's lymphoma study group 显示文摘 | Hiddeman W Unterhalt M Port C | 1993 | Semin oncol1993，20，1： | 1 |
| 11 | IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas:results of a phase-Ⅱ study of the German low-Grade Lymphoma Study Group显示文摘 | Feuring-Buske M Kneda M Unterhalt M | | Deutsche Medizin0，，： | 1 |
| 12 | Effect of the addition of rituximab to front line therapy with cyclophosphamide,doxorubicin,vincristine and time to treatment failure (TTF) compared to CHOP alone in mantle cell lymphoma (MCL):results of a prospective randomized trial of the German Low Grade Lymphoma Study Group(GLSG)显示文摘 | Hiddemann W Dreyling M Unterhalt M | 2004 | Proc Am Soc Clin Oncol2004，22，14： | 1 |
| 13 | Effect of the addition of rituximab to front line therapy with cyclophosphamide, doxorubicin, vincristine and time to treatment failure(TTF) compared to CHOP alone in mantle cell lymphoma(MCL): resuhs of a prospective randomizedtrial of the German Low Grade Lymphoma Study Group(C-LSG) 显示文摘 | Hiddemann W Dreyling M Unterhalt M | 2004 | Proc Am Soc Clin Oncol2004，22，14： | 1 |
| 14 | Recent advances in antigen-targeted therapy in non-Hodgkin's |ymphoma显示文摘 | Feuring Buske M Buske C Unterhalt M | 2000 | Ann Hematol2000，79，4： | 1 |
| 15 | High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with ref ractory acute leukemias显示文摘 | Kern W Schleyer E Unterhalt M | 1997 | Cancer1997，79，1： | 1 |
| 16 | NPMI, but not FLT3- ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high risk myelodysplastic syndrome (MDS) 显示文摘 | Schneider F Hoster E Unterhalt M | 2009 | Blood2009，113，21： | 1 |
| 17 | IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas:results of a phase-Ⅱ study of the German Low-Grade Lymphoma Study Group显示文摘 | Feuring-Buske M Kneba M Unterhalt M | 2000 | Ann Hematol2000，79，9： | 1 |
| 18 | Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG 显示文摘 | Fiegl M Unterhalt M Kern W | 2014 | Leukemia2014，28，5： | 1 |
| 19 | Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)显示文摘 | FORSTPOINTNER R UNTERHALT M DREYLING M | 2006 | Blood2006，108，13： | 1 |
| 20 | Maintenance therapy with rituximab leads to a significant prolongation of re- sponse duration after salvage therapy with a combination of ritux- imab, fludarabine, cyclophosphamide, and mitoxantrone (R- FCM) in patients with recurring and refractory follicular and man- tle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG) 显示文摘 | Forstpointner R Unterhalt M Dreyling M | 2006 | Blood2006，108，13： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员